OLMA

Company Overview — What Does Olema Pharmaceuticals, Inc. Do?

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California. Olema Pharmaceuticals, Inc. (OLMA) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Sean Bohen and employs approximately 70 people. With a market capitalization of $1.3B, OLMA is one of the notable companies in the Healthcare sector.

Olema Pharmaceuticals, Inc. (OLMA) Stock Rating — Reduce (April 2026)

As of April 2026, Olema Pharmaceuticals, Inc. receives a Reduce rating with a composite score of 39.4/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.OLMA ranks #3,117 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Olema Pharmaceuticals, Inc. ranks #454 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

OLMA Stock Price and 52-Week Range

Olema Pharmaceuticals, Inc. (OLMA) currently trades at $15.98. The stock lost $0.66 (4.0%) in the most recent trading session. The 52-week high for OLMA is $36.26, which means the stock is currently trading -55.9% from its annual peak. The 52-week low is $2.86, putting the stock 458.7% above its annual trough. Recent trading volume was 1.2M shares, reflecting moderate market activity.

Is OLMA Overvalued or Undervalued? — Valuation Analysis

Olema Pharmaceuticals, Inc. (OLMA) carries a value factor score of 22/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 2.78x, versus the sector average of 2.75x.

At current multiples, Olema Pharmaceuticals, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Olema Pharmaceuticals, Inc. Profitability — ROE, Margins, and Quality Score

Olema Pharmaceuticals, Inc. (OLMA) earns a quality factor score of 26/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -31.5%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -28.3% versus the sector average of -33.1%.

Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

OLMA Debt, Balance Sheet, and Financial Health

Olema Pharmaceuticals, Inc. has a debt-to-equity ratio of 11.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 9.95x, indicating strong short-term liquidity. Total debt on the balance sheet is $3M. Cash and equivalents stand at $35M.

OLMA has a beta of 0.23, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for Olema Pharmaceuticals, Inc. is 32/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Olema Pharmaceuticals, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Olema Pharmaceuticals, Inc. reported revenue of $0 and earnings per share (EPS) of $-1.87. Net income for the quarter was $-151M. Operating income came in at $-166M.

In FY 2025, Olema Pharmaceuticals, Inc. reported revenue of $0 and earnings per share (EPS) of $-1.87. Net income for the quarter was $-162M. Operating income came in at $-179M.

In Q3 2025, Olema Pharmaceuticals, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.49. Net income for the quarter was $-42M. Operating income came in at $-46M.

In Q2 2025, Olema Pharmaceuticals, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.51. Net income for the quarter was $-44M. Operating income came in at $-48M.

Over the past 8 quarters, Olema Pharmaceuticals, Inc. has experienced revenue contraction from $0 to $0. Investors analyzing OLMA stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

OLMA Dividend Yield and Income Analysis

Olema Pharmaceuticals, Inc. (OLMA) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

OLMA Momentum and Technical Analysis Profile

Olema Pharmaceuticals, Inc. (OLMA) has a momentum factor score of 63/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 68/100 reflects moderate short selling activity.

OLMA vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Olema Pharmaceuticals, Inc. (OLMA) ranks #454 out of 838 stocks based on the Blank Capital composite score. This places OLMA in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing OLMA against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full OLMA vs S&P 500 (SPY) comparison to assess how Olema Pharmaceuticals, Inc. stacks up against the broader market across all factor dimensions.

OLMA Next Earnings Date

No upcoming earnings date has been announced for Olema Pharmaceuticals, Inc. (OLMA) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy OLMA? — Investment Thesis Summary

The quantitative profile for Olema Pharmaceuticals, Inc. suggests caution. The quality score of 26/100 flags below-average profitability. The value score of 22/100 indicates premium valuation. Price momentum is positive at 63/100, suggesting the trend favors buyers. High volatility (stability score 32/100) increases portfolio risk.

In summary, Olema Pharmaceuticals, Inc. (OLMA) earns a Reduce rating with a composite score of 39.4/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on OLMA stock.

Related Resources for OLMA Investors

Explore more research and tools: OLMA vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare OLMA head-to-head with peers: OLMA vs AZN, OLMA vs SLGL, OLMA vs VMD.